Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Linda B Couto

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Seminars in Thrombosis and Hemostasis|May 1, 2004
Preclinical gene therapy studies for hemophilia using adeno-associated virus (AAV) vectorsLinda B Couto
Current Opinion in Pharmacology|July 13, 2010
Viral vector-mediated RNA interferenceLinda B Couto, Katherine A High
Current Opinion in Molecular Therapeutics|November 7, 2003
AAV-mediated gene therapy for hemophiliaLinda B Couto, Glenn F Pierce
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 9, 2013
Preclinical evaluation of an anti-HCV miRNA cluster for treatment of HCV infectionXiao Yang, Katherine Marcucci, Xavier Anguela, et al.
Human Gene Therapy|April 7, 2005
Modified infusion procedures affect recombinant adeno-associated virus vector type 2 transduction in the liverKazuo Ohashi, Hiroyuki Nakai, Linda B Couto, et al.
Hepatology (Baltimore, Md.)|October 9, 2010
Inhibition of hepatitis C virus replication using adeno-associated virus vector delivery of an exogenous anti-hepatitis C virus microRNA clusterXiao Yang, Virginia Haurigot, Shangzhen Zhou, et al.
Blood|October 27, 2005
Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID miceCiaran D Scallan, Haiyan Jiang, Tongyao Liu, et al.
Molecular Therapy. Methods & Clinical Development|March 19, 2025
Validation of a quantitative cell-based relative potency assay for LUXTURNAKatherine A High, Dave Le Blond, Karen Doucette, et al.
Blood|October 14, 2004
Regional intravascular delivery of AAV-2-F.IX to skeletal muscle achieves long-term correction of hemophilia B in a large animal modelValder R Arruda, Hansell H Stedman, Timothy C Nichols, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 25, 2006
Inadvertent germline transmission of AAV2 vector: findings in a rabbit model correlate with those in a human clinical trialJoerg Schuettrumpf, Jian-Hua Liu, Linda B Couto, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Seminars in Thrombosis and Hemostasis|May 1, 2004
Preclinical gene therapy studies for hemophilia using adeno-associated virus (AAV) vectorsLinda B Couto
Current Opinion in Pharmacology|July 13, 2010
Viral vector-mediated RNA interferenceLinda B Couto, Katherine A High
Current Opinion in Molecular Therapeutics|November 7, 2003
AAV-mediated gene therapy for hemophiliaLinda B Couto, Glenn F Pierce
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 9, 2013
Preclinical evaluation of an anti-HCV miRNA cluster for treatment of HCV infectionXiao Yang, Katherine Marcucci, Xavier Anguela, et al.
Human Gene Therapy|April 7, 2005
Modified infusion procedures affect recombinant adeno-associated virus vector type 2 transduction in the liverKazuo Ohashi, Hiroyuki Nakai, Linda B Couto, et al.
Hepatology (Baltimore, Md.)|October 9, 2010
Inhibition of hepatitis C virus replication using adeno-associated virus vector delivery of an exogenous anti-hepatitis C virus microRNA clusterXiao Yang, Virginia Haurigot, Shangzhen Zhou, et al.
Blood|October 27, 2005
Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID miceCiaran D Scallan, Haiyan Jiang, Tongyao Liu, et al.
Molecular Therapy. Methods & Clinical Development|March 19, 2025
Validation of a quantitative cell-based relative potency assay for LUXTURNAKatherine A High, Dave Le Blond, Karen Doucette, et al.
Blood|October 14, 2004
Regional intravascular delivery of AAV-2-F.IX to skeletal muscle achieves long-term correction of hemophilia B in a large animal modelValder R Arruda, Hansell H Stedman, Timothy C Nichols, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 25, 2006
Inadvertent germline transmission of AAV2 vector: findings in a rabbit model correlate with those in a human clinical trialJoerg Schuettrumpf, Jian-Hua Liu, Linda B Couto, et al.
Pageof 2